These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7718903)

  • 1. Evaluation of CD38 as target for immunotherapy in multiple myeloma.
    Vooijs WC; Schuurman HJ; Bast EJ; de Gast GC
    Blood; 1995 Apr; 85(8):2282-4. PubMed ID: 7718903
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma.
    Goldmacher VS; Bourret LA; Levine BA; Rasmussen RA; Pourshadi M; Lambert JM; Anderson KC
    Blood; 1994 Nov; 84(9):3017-25. PubMed ID: 7524764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody.
    Stevenson FK; Bell AJ; Cusack R; Hamblin TJ; Slade CJ; Spellerberg MB; Stevenson GT
    Blood; 1991 Mar; 77(5):1071-9. PubMed ID: 1995092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of murine CD38 defines a population of long-term reconstituting hematopoietic stem cells.
    Randall TD; Lund FE; Howard MC; Weissman IL
    Blood; 1996 May; 87(10):4057-67. PubMed ID: 8639761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a monoclonal antibody to plasma cells: a comparison with CD38 and PCA-1.
    Hata H; Matsuzaki H; Matsuno F; Sonoki T; Takemoto S; Kuribayashi N; Nagasaki A; Takatsuki K
    Clin Exp Immunol; 1994 May; 96(2):370-5. PubMed ID: 8187346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
    Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
    Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD38 in hematopoietic malignancies.
    Konopleva M; Rissling I; Andreeff M
    Chem Immunol; 2000; 75():189-206. PubMed ID: 10851785
    [No Abstract]   [Full Text] [Related]  

  • 8. Functional differences between CD38- and DR- subfractions of CD34+ bone marrow cells.
    Rusten LS; Jacobsen SE; Kaalhus O; Veiby OP; Funderud S; Smeland EB
    Blood; 1994 Sep; 84(5):1473-81. PubMed ID: 7520773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma.
    Kimlinger T; Witzig TE
    Bone Marrow Transplant; 1997 Mar; 19(6):553-6. PubMed ID: 9085734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leu-19 in myeloma--a new role for an old antibody.
    Wetter O; Brandhorst D; Reiter W
    Eur J Cancer; 1990 Apr; 26(4):541. PubMed ID: 1694090
    [No Abstract]   [Full Text] [Related]  

  • 11. Multiple myeloma: expression of nucleoside transporters on malignant plasma cells and their relationship to cellular proliferation.
    Petersen AJ; Brown RD; Pope BB; Jamieson GP; Paterson AR; Gibson J; Wiley JS; Joshua DE
    Leuk Lymphoma; 1994 May; 13(5-6):491-9. PubMed ID: 8069194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies to human tumor antigens.
    Wright GL; Cox AD
    Curr Top Pathol; 1987; 77():1-18. PubMed ID: 3322690
    [No Abstract]   [Full Text] [Related]  

  • 13. Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia.
    Turhan AG; Lemoine FM; Debert C; Bonnet ML; Baillou C; Picard F; Macintyre EA; Varet B
    Blood; 1995 Apr; 85(8):2154-61. PubMed ID: 7536493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: novel responses to Flt3-ligand and thrombopoietin.
    Petzer AL; Zandstra PW; Piret JM; Eaves CJ
    J Exp Med; 1996 Jun; 183(6):2551-8. PubMed ID: 8676076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells.
    Yi Q; Dabadghao S; Osterborg A; Bergenbrant S; Holm G
    Blood; 1997 Sep; 90(5):1960-7. PubMed ID: 9292530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization.
    Goulet AC; Goldmacher VS; Lambert JM; Baron C; Roy DC; Kouassi E
    Blood; 1997 Sep; 90(6):2364-75. PubMed ID: 9310487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of cell surface markers during differentiation of CD34+, CD38-/lo fetal and adult bone marrow cells.
    Olweus J; Lund-Johansen F; Terstappen LW
    Immunomethods; 1994 Dec; 5(3):179-88. PubMed ID: 7540098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells.
    Gazitt Y
    Leukemia; 1999 Nov; 13(11):1817-24. PubMed ID: 10557057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the growth properties of CD34+, CD38- bone marrow progenitors during human fetal development.
    Waller EK; Huang S; Terstappen L
    Blood; 1995 Jul; 86(2):710-8. PubMed ID: 7541673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Release from quiescence of CD34+ CD38- human umbilical cord blood cells reveals their potentiality to engraft adults.
    Cardoso AA; Li ML; Batard P; Hatzfeld A; Brown EL; Levesque JP; Sookdeo H; Panterne B; Sansilvestri P; Clark SC
    Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8707-11. PubMed ID: 7690969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.